PHAXIAM Therapeutics S.A. Statistics Share Statistics PHAXIAM Therapeutics S.A. has 6.4M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 6.4M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 4.51M Failed to Deliver (FTD) Shares 242 FTD / Avg. Volume 12.81%
Short Selling Information The latest short interest is 1.15K, so 0% of the outstanding
shares have been sold short.
Short Interest 1.15K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.87 and the forward
PE ratio is null.
PHAXIAM Therapeutics S.A.'s PEG ratio is
0.
PE Ratio -0.87 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.8 P/FCF Ratio -0.83 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for PHAXIAM Therapeutics S.A..
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.06,
with a Debt / Equity ratio of 0.43.
Current Ratio 1.06 Quick Ratio 1.06 Debt / Equity 0.43 Debt / EBITDA -0.46 Debt / FCF -0.44 Interest Coverage -129.68
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-479.35K Employee Count 49 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.25M Effective Tax Rate 5.04%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.8, so PHAXIAM Therapeutics S.A.'s
price volatility has been higher than the market average.
Beta 1.8 52-Week Price Change n/a 50-Day Moving Average 4.03 200-Day Moving Average 5.29 Relative Strength Index (RSI) 41.33 Average Volume (20 Days) 1,889
Income Statement
Revenue n/a Gross Profit -1.61M Operating Income -25.42M Net Income -23.49M EBITDA -23.81M EBIT -24.54M Earnings Per Share (EPS) -4.62
Full Income Statement Balance Sheet The company has 10.47M in cash and 10.92M in
debt, giving a net cash position of -443K.
Cash & Cash Equivalents 10.47M Total Debt 10.92M Net Cash -443K Retained Earnings n/a Total Assets 51.31M Working Capital 955K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -24.37M
and capital expenditures -217K, giving a free cash flow of -24.58M.
Operating Cash Flow -24.37M Capital Expenditures -217K Free Cash Flow -24.58M FCF Per Share -4.84
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PHXM does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for PHXM.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 20, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Sep 20, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -1.24 Piotroski F-Score 3
